GlassScriptPhysician profile
Randal Macurak
NPI 1861451502
$7,162.92
in general payments reported to CMS, 2019-2025
23 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,731 · 2020: $318 · 2021: $822 · 2022: $1,160 · 2023: $675 · 2024: $783 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.80 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gi Supply, INC. | $2,350.00 | 2019 | |
| Abbvie INC. | $1,773.30 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,509.32 | 2019-2025 | Xifaxan, Trulance |
| Ipsen Biopharmaceuticals, INC | $302.48 | 2023-2025 | Iqirvo, Bylvay |
| Merck Sharp & Dohme LLC | $186.31 | 2020-2024 | Dificid |
| Celgene Corporation | $185.56 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $150.95 | 2019-2025 | Suflave |
| Qol Medical, LLC | $109.15 | 2021-2023 | Sucraid |
| Genzyme Corporation | $101.27 | 2023-2024 | |
| Janssen Biotech, INC. | $93.01 | 2021-2024 | Stelara |
| Regeneron Healthcare Solutions, INC. | $65.99 | 2024 | Dupixent |
| Celltrion USA INC. | $57.02 | 2024-2025 | Vegzelma |
| Evoke Pharma, INC. | $42.63 | 2022-2023 | Gimoti |
| Takeda Pharmaceuticals U.S.A., INC. | $41.90 | 2019-2025 | Entyvio |
| Pfizer INC. | $36.92 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $31.86 | 2024 | |
| Intra-Sana Laboratories | $28.14 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Lilly USA, LLC | $25.39 | 2025 | Omvoh |
| Ardelyx, INC. | $25.14 | 2024 | Ibsrela |
| Novo Nordisk INC | $16.50 | 2025 | Wegovy |
| Alfasigma USA, INC. | $16.28 | 2020 | |
| Vivus LLC | $13.80 | 2024 | Qsymia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,785.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randal Macurak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.